Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1 Hassan Al-Dhibi,1 Abdulelah A Al-Abdullah1 1King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; 2King Abdullah Medical City, Makkah, Saudi Arabia; 3College of Medicine, King Saud University, R...

Full description

Bibliographic Details
Main Authors: Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA
Format: Article
Language:English
Published: Dove Medical Press 2021-07-01
Series:Clinical Ophthalmology
Subjects:
aflibercept
bevacizumab
persistent dme
ranibizumab
vegf switch
vascular endothelial growth factor
Online Access:https://www.dovepress.com/aflibercept-versus-ranibizumab-as-a-second-line-therapy-after-bevacizu-peer-reviewed-fulltext-article-OPTH

Internet

https://www.dovepress.com/aflibercept-versus-ranibizumab-as-a-second-line-therapy-after-bevacizu-peer-reviewed-fulltext-article-OPTH

Similar Items